Results 281 to 290 of about 9,263,948 (394)

Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease

Cancer, 1999
R. Williams, R. Littell, N. Mendenhall
semanticscholar   +1 more source

Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T‐cell responses and anti‐tumor immunity by targeting conventional type 1 dendritic cells

Immunology &Cell Biology, EarlyView.
Therapeutic cancer vaccines require CD8+ T‐cell activation for efficacy. This response can be enhanced by rationally designing polymeric nanoparticle adjuvants. The importance of antigen location for the adjuvanticity of polymeric nanoparticles has not been fully resolved.
Jorge Huete‐Carrasco, Jingjing Zhu, Benoit J Van den Eynde, Christian Thomas Mayer, Tim Sparwasser, Ross W Ward, Ed C Lavelle   +6 more
wiley   +1 more source

Global burden and trends of childhood non-Hodgkin lymphoma from 1990 to 2021. [PDF]

Front Pediatr
Xie J, Xu JS, Huang JW, Zheng YS.
europepmc   +1 more source

Acute Hodgkins Disease [PDF]

Acta Radiologica, 1952
openaire   +2 more sources

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma. [PDF]

Eur J Haematol
Robin A, Owen C, Perry S, Street L, Chua N, Stewart D, Puckrin R.   +6 more
europepmc   +1 more source

Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study identifies a progressive decline in overall survival with each 10% increase in BSA in early‐stage mycosis fungoides. A new BSA cut‐off of 40% is proposed as a significant prognostic factor for patients with patch/plaque‐stage disease, with potential therapeutic consequences.
Juliette M. Kersten, Rosanne Ottevanger, Koen D. Quint, Maarten H. Vermeer, Jelle J. Goeman, Youn Kim, Felicity Evison, Julia J. Scarisbrick, Rein Willemze   +8 more
wiley   +1 more source

ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical hodgkin lymphoma: a retrospective cohort study. [PDF]

Cancer Imaging
Pinczés LI, Tóthfalusi D, Dobó B, Barna S, Farkas B, Garai I, Illés Á, Miltényi Z.   +7 more
europepmc   +1 more source

Gaucher disease, state of the art and perspectives

Journal of Internal Medicine, EarlyView.
Abstract Knowledge about Gaucher disease (GD), considered a model for rare diseases, has considerably increased since its discovery. The pathophysiology of this lysosomal disorder is better known, and specific therapies that can control many aspects of the disease have been developed, particularly for the most common form, Type 1 GD.
Fabrice Camou, Marc G. Berger
wiley   +1 more source

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results. [PDF]

Blood Adv
Cheson BD, Bartlett NL, Knopf B, Lee HJ, Advani RH, Christian B, Diefenbach CS, Feldman TA, Ansell SM.   +8 more
europepmc   +1 more source